Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Australia ETF (EWA) vs Viatris Inc (VTRS) Price & Performance

iShares MSCI Australia ETFTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Australia ETF vs Viatris Inc — how do they compare? iShares MSCI Australia ETF trades at $29.91, while Viatris Inc trades at $16.27 (market cap $18.69B). The key difference: Viatris Inc pays a 2.95% dividend while iShares MSCI Australia ETF pays none. Which is the better fit depends on your goals.

EWAVTRS
Sector
Broad Market / FactorHealth
52-Week High
$30.41$17.86
52-Week Low
$24.95$9.49
Market Cap
$18.69B
Enterprise Value
$30.80B
Dividend Yield
2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Australia ETF

EWA trades at $29.985, down 0.22% on the day, with a bullish technical signal from moving averages and strong trend strength indicated by ADX readings. The stock shows neutral momentum oscillators, and support/resistance levels are consolidated around $30. A dividend of $0.40 is scheduled for June 2026, providing income potential.

Outlook remains cautiously optimistic given technical strength, but fundamental data is unavailable for valuation assessment. Risks include reliance on Australian economic conditions and sector-specific headwinds. Investors should seek updated financials for a complete view amid mixed sentiment.

Viatris Inc

Viatris (VTRS) trades at $16.28, down 0.91% on the day, with a bearish technical signal and mixed fundamentals. The company reported a net loss of $3.51 billion in 2025 despite recent quarterly earnings beats, including Q2 2026 EPS of $0.69 versus $0.62 expected. Revenue declined to $14.30 billion in 2025, but operational cash flow remains strong at $2.32 billion. Recent news highlights divestitures and FDA approval for Gwyn Lo, a contraceptive patch.

Outlook is cautious due to persistent losses and high P/E of 236.2, but dividend payments and cost-cutting efforts offer stability. Risks include competitive pressures and debt levels, while analyst consensus leans hold. The stock's value hinges on margin improvement and debt reduction progress.

Returns comparison

Trailing returns across standard periods

About iShares MSCI Australia ETF

EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.

Read more on EWA

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS